Recent Research Analysts’ Ratings Updates for NewAmsterdam Pharma (NAMS)

A number of research firms have changed their ratings and price targets for NewAmsterdam Pharma (NASDAQ: NAMS):

• 11/6/2025 – NewAmsterdam Pharma had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an “outperform” rating on the stock.
• 11/5/2025 – NewAmsterdam Pharma had its price target raised by analysts at Needham & Company LLC from $40.00 to $46.00. They now have a “buy” rating on the stock.
• 10/20/2025 – NewAmsterdam Pharma is now covered by analysts at HC Wainwright. They set a “buy” rating and a $52.00 price target on the stock.
• 10/20/2025 – NewAmsterdam Pharma is now covered by analysts at HC Wainwright. They set a “buy” rating and a $52.00 price target on the stock.
• 10/17/2025 – NewAmsterdam Pharma had its price target raised by analysts at Citigroup Inc. from $42.00 to $50.00. They now have a “buy” rating on the stock.
• 10/8/2025 – NewAmsterdam Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – NewAmsterdam Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the transaction, the chief accounting officer directly owned 15,000 shares of the company’s stock, valued at $387,450. The trade was a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of NewAmsterdam Pharma stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the transaction, the insider directly owned 119,302 shares of the company’s stock, valued at approximately $2,897,845.58. This trade represents a 29.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders bought 2,391 shares of company stock valued at $58,424 and sold 226,342 shares valued at $5,748,019. 20.84% of the stock is owned by company insiders.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.